drugset / Trial / NCT07622771
Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial
RandomizedParallel-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of radiotherapy combined with Adebrelimab and NALIRIFOX in patients with pMMR/MSS locally advanced rectal cancer
Timeline
- Start
- 2026-06-01
- Primary completion
- 2028-06-30
- Completion
- 2032-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | — |
| Background | Adalimumab | Monoclonal antibody | 200 mg/m2 | — |
| Background | Adalimumab | Monoclonal antibody | 1200 mg | — |
| Background | Irinotecan | Small molecule | 60 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | — |